Source-grounded facts extracted from Korro Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Korro Bio, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-10 meeting.
“Korro’s stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm”
Korro Bio, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-10 meeting.
“Korro’s stockholders approved, in a non-binding, advisory vote, the compensation of Korro’s named executive officers”
Korro Bio, Inc. shareholders approved Election of Class I Directors at the 2026-06-10 meeting.
“Korro’s stockholders elected each of Nessan Bermingham and Rachel Meyers as Class I directors”
Korro Bio, Inc. reported first quarter ended March 31, 2026 results: net income $19.6 million.
“Korro’s net loss was $19.6 million for the three months ended March 31, 2026”
Korro Bio, Inc. reported the fiscal year ended December 31, 2025 results: revenue $6.4 million.
“There was $6.4 million of collaboration revenue for the year ended December 31, 2025, as compared to $2.3 million for the year ended December 31, 2024.”
Korro Bio, Inc. reported financial results for the fourth quarter ended December 31, 2025.
“Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.”
Korro Bio, Inc. issued 3,148,836 shares of warrant to institutional accredited investors for $11.109 per pre-funded warrant.
“pre-funded warrants to acquire an aggregate of 3,148,836 shares of its common stock at a purchase price of $11.109 per pre-funded warrant”
Korro Bio, Inc. issued 4,501,928 shares of common stock to institutional accredited investors for $11.11 per share.
“4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an aggregate of 4,501,928 shares of its common stock, par value $0.001 per share at a purchase price of $11.11 per share and (ii) pre-funded warrants to acquire an aggregate of 3,148,836 shares of its common stock at a purchase price of $11.109 per pre-funded warrant. The private placement”
Korro Bio, Inc. entered into subscription agreement with a number of institutional accredited investors valued at approximately $85.0 million (effective 2026-03-09).
“Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement”
Korro Bio, Inc. announced a restructuring with charges of approximately $2.4 million (approximately 34%).
“On November 12, 2025, Korro implemented a strategic restructuring to extend cash runway, including a workforce reduction of approximately 34%. Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended December 31, 2025.”
Korro Bio, Inc. announced a restructuring with charges of approximately $1.2 million (approximately 20%).
“Korro estimates that it will incur one-time restructuring charges of approximately $1.2 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended June 30, 2025.”
Oliver Dolan was appointed as Principal Accounting Officer at Korro Bio, Inc..
“the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.”
Ram Aiyar changed role as President and Chief Executive Officer at Korro Bio, Inc..
“Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).”
Vineet Agarwal was appointed as Chief Financial Officer at Korro Bio, Inc..
“Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.”
Oliver Dolan was appointed as Interim Principal Accounting Officer at Korro Bio, Inc..
“and Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer”
Ram Aiyar was appointed as Interim Principal Financial Officer at Korro Bio, Inc..
“Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer”
Vineet Agarwal changed role as Chief Financial Officer at Korro Bio, Inc..
“Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.”
Katharine Knobil, M.D. was appointed as Director at Korro Bio, Inc..
“and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.”
David L. Lucchino resigned as Director at Korro Bio, Inc..
“On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.”
Steve Colletti resigned as Chief Scientific Officer at Korro Bio, Inc..
“On June 17, 2024, Steve Colletti, Ph.D., notified Korro Bio, Inc. of his intent to resign as its Chief Scientific Officer effective August 2, 2024.”
Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.
“Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024”
Korro Bio, Inc. entered into Subscription Agreement with a number of institutional accredited investors valued at approximately $70.0 million (effective 2024-04-17).
“On April 17, 2024, we entered into a subscription agreement with a number of institutional accredited investors pursuant to which we agreed to sell and issue in a private placement”
Korro Bio, Inc. reported the year ended December 31, 2023 results: net income $81.2 million.
“Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.”
Rachel Meyers, Ph.D. was appointed as Class I Director at Korro Bio, Inc..
“On November 27, 2023, upon the recommendation of its Nominating and Corporate Governance Committee, or the NCG Committee, our Board of Directors, or the Board, appointed Rachel Meyers, Ph.D. as a Class I director, effective November 27, 2023”
Korro Bio, Inc.: Amended and restated the Code of Conduct and Ethics in connection with the Merger.
“the Board amended and restated our Code of Conduct and Ethics.”
Korro Bio, Inc.: Filed a second certificate of amendment to change the company name to 'Korro Bio, Inc.', effective upon filing on November 3, 2023 (effective 2023-11-03).
“we filed a second certificate of amendment to the Charter”
Korro Bio, Inc.: Approved and filed a certificate of amendment to effect a 1:50 reverse stock split, effective upon filing on November 3, 2023 (effective 2023-11-03).
“stockholders approved an amendment to our restated certificate of incorporation”
Korro Bio, Inc. shareholders approved Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2 at the 2023-11-03 meeting.
“Proposal 7 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 1 and 2. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 10,980,682 808,960 324,296 11,937,522”
Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan at the 2023-11-03 meeting.
“Proposal 6 - Approval of the Korro Bio, Inc. 2023 Employee Stock Purchase Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 8,145,970 3,641,499 326,369 11,937,522”
Korro Bio, Inc. shareholders approved Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan at the 2023-11-03 meeting.
“Proposal 5 - Approval of the Korro Bio, Inc. 2023 Stock Option and Incentive Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 6,321,270 5,464,618 328,050 11,937,522”
Korro Bio, Inc. shareholders approved Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023 at the 2023-11-03 meeting.
“Proposal 4 - Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 23,049,119 329,237 673,104 0”
Korro Bio, Inc. shareholders approved Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified at the 2023-11-03 meeting.
“Proposal 3 - Election of one Class I director to serve until the 2026 Annual Meeting of Stockholders, and until his successor has been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David L. Lucchino 9,100,124 3,013,814 11,937,522”
Korro Bio, Inc. shareholders approved Approval of the amendment to the Charter effecting the reverse stock split at the 2023-11-03 meeting.
“Proposal 2 - Approval of the amendment to the Charter effecting the reverse stock split. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,748,459 1,021,963 281,038 0”
Korro Bio, Inc. shareholders approved Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger at the 2023-11-03 meeting.
“Proposal 1 - Approval of the issuance of common stock in the Merger and the change in control resulting from the Merger. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,505,632 383,292 225,014 11,937,522”
Korro Bio, Inc. underwent a change of control involving Korro Bio, Inc. (Legacy Korro) (closed 2023-11-03).
“On November 3, 2023, we completed the previously announced business combination with Legacy Korro in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Korro, with Legacy Korro surviving as our wholly owned subsidiary (such business combination, the Merger).”
Korro Bio, Inc. engaged Ernst & Young LLP as its auditor.
“Appointment of New Independent Registered Public Accounting Firm Ernst & Young LLP, or E&Y, served as the independent registered public accounting firm of Legacy Korro prior to the completion of the Merger.”
Korro Bio, Inc. dismissed RSM US LLP as its auditor.
“On November 3, 2023, following the completion of the Merger, RSM was dismissed as our independent registered public accounting firm.”
Timothy Pearson was appointed as Director at Korro Bio, Inc..
“Timothy Pearson (designated by mutual agreement)”
Jean-Francois Formela was appointed as Director at Korro Bio, Inc..
“Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)”
Nessan Bermingham was appointed as Chairperson of the Board at Korro Bio, Inc..
“Nessan Bermingham was appointed Chairperson of the Board.”
Ali Behbahani was appointed as Director at Korro Bio, Inc..
“Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)”
Ram Aiyar was appointed as Director at Korro Bio, Inc..
“Ram Aiyar, Ali Behbahani, Nessan Bermingham and Jean-Francois Formela (designated by Legacy Korro)”
Ram Aiyar was appointed as Chief Executive Officer at Korro Bio, Inc..
“Ram Aiyar, Ph.D., M.B.A. Dr. Aiyar has served as our Chief Executive Officer and a director since completion of the Merger.”
David Lucchino was appointed as Director at Korro Bio, Inc..
“the Board was reconstituted as follows: (i) David L. Lucchino (designated by Frequency)”
David Lucchino resigned as President and Chief Executive Officer at Korro Bio, Inc..
“Immediately after closing of the Merger, David Lucchino, resigned as our President and Chief Executive Officer and principal executive officer.”
Robert S. Langer resigned as Director at Korro Bio, Inc..
“Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served”
Michael Huang resigned as Director at Korro Bio, Inc..
“Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served”
Cynthia L. Feldmann resigned as Director at Korro Bio, Inc..
“Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served”
Timothy J. Barberich resigned as Director at Korro Bio, Inc..
“Timothy J. Barberich, Cynthia L. Feldmann, Michael Huang and Robert S. Langer resigned from the Board and committees of the Board on which they respectively served”
Korro Bio, Inc. terminated Sales Agreement with Oppenheimer & Co. Inc. (effective 2023-09-26).
“On September 26, 2023, the Company delivered written notice to Oppenheimer of termination of the Sales Agreement pursuant to Section 11(b) thereof, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.